Invivyd IVVD
NASDAQ IVVD
$0.83 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Invivyd (IVVD) Share-based Compensation (2020 - 2026)

Invivyd's (IVVD) quarterly Share-based Compensation came in at $30.2 million in Q2 2026, up 42.48% on a YoY basis from $21.2 million in Q2 2025, and up 1078.95% quarter-over-quarter from $2.6 million in Q4 2025.

Analysis

Invivyd (IVVD) Share-based Compensation (2020 - 2026) Analysis & Trends

Invivyd (IVVD) has reported Share-based Compensation for 7 consecutive years, with $30.2 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Share-based Compensation rose 42.48% year-over-year to $30.2 million; the trailing twelve-month figure through Jun 2026 stood at $30.2 million (up 42.48% YoY), and the FY2025 full-year result was $21.4 million, up 7.9% from the prior year.
  • Share-based Compensation improved to $30.2 million in Q2 2026 per IVVD's latest filing, from $2.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $30.2 million in Q2 2026 and bottomed at $2.6 million in Q4 2025.
  • Historically, Share-based Compensation has averaged $18.5 million across 5 years, with a median of $21.4 million in 2022.
  • The sharpest annual moves came in 2022 and 2024: Share-based Compensation soared 3262.51% in 2022, then slipped 29.63% in 2024.
  • Over 5 years, Share-based Compensation stood at $5.9 million in 2022, then slipped by 26.44% to $4.3 million in 2023, then retreated by 29.63% to $3.1 million in 2024, then retreated by 16.13% to $2.6 million in 2025, then surged by 1078.95% to $30.2 million in 2026.
  • According to Business Quant data, Share-based Compensation over the past three periods registered $30.2 million, $2.6 million, and $21.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 247.00 Mn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 231.00 Mn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 108.10 Mn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 243.00 Mn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn -
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn 120.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 86.63 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 77.40 Mn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn 41.25 Mn
10 Invivyd 244.65 Mn 84.57 Mn 13.01 Mn 30.23 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 30.23 Mn
Dec 31, 2025 2.56 Mn
Sep 30, 2025 21.32 Mn
Jun 30, 2025 21.22 Mn
Mar 31, 2025 23.01 Mn
Dec 31, 2024 3.06 Mn
Sep 30, 2024 21.88 Mn
Jun 30, 2024 25.03 Mn
Mar 31, 2024 26.36 Mn
Dec 31, 2023 4.34 Mn
Sep 30, 2023 22.05 Mn
Jun 30, 2023 21.82 Mn
Mar 31, 2023 23.88 Mn
Dec 31, 2022 5.91 Mn
Sep 30, 2022 21.40 Mn
Jun 30, 2022 19.94 Mn
Mar 31, 2022 19.74 Mn
Dec 31, 2021 7.86 Mn
Sep 30, 2021 17.46 Mn
Jun 30, 2021 14.93 Mn